Hepatobiliary Tumors Tissue Samples Acquisition
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Benign Hepatobiliary Disease
- Biliary Tract Cancer
- Cholangiocarcinoma
- Gallbladder Cancer
- Healthy, no Evidence of Disease
- Hepatocellular Carcinoma
- Liver Cancer
- Precancerous Condition
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
OBJECTIVES: Observe the biomarkers of resectable hepatobiliary tumor recurrence (DFS) and survival (OS); Observe the evolution of tumors and discover specific diagnostic markers as a control group. Observe the response (ORR), progression (PFS) and survival (OS) biomarkers of targeted immunotherapy f...
OBJECTIVES: Observe the biomarkers of resectable hepatobiliary tumor recurrence (DFS) and survival (OS); Observe the evolution of tumors and discover specific diagnostic markers as a control group. Observe the response (ORR), progression (PFS) and survival (OS) biomarkers of targeted immunotherapy for advanced hepatobiliary tumors; To elaborate on the multi-omics study of hepatobiliary tumors, to further subtype and find therapeutic targets
Tracking Information
- NCT #
- NCT04445532
- Collaborators
- OrigiMed
- GeneCast Biotechnology Co., Ltd.
- YuceBio Technology Co., Ltd.
- Investigators
- Principal Investigator: Haitao Zhao, MD Peking Union Medical College Hospital